Tele: 561.316.3330
Breaking Medical Device News

Tuesday, October 19, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR

MARKET REPORTS

Global $45 Billion Endoscopy Market Insights & Forecasts to 2025

The global endoscopy market is predicted to reach US$45.28 billion in 2025, growing, at a CAGR of 7.50%, for the duration spanning 2021-2025.

Global Remote Monitoring Devices Market Research Report (2021 to 2026)

Global Remote Monitoring Devices Market size was estimated at USD 1,035.35 million in 2020, is expected to reach USD 1,170.22 million in 2021.

Research Efforts Fuel the Future of Global Obstructive Lung Disease Management Markets – ResearchAndMarkets.com

The "Global Obstructive Lung Disease Management Research Report" report has been added.

Global Electrophysiology Market (2021 to 2026) – Growth, Trends , COVID-19 Impact and Forecasts – ResearchAndMarkets.com

The Electrophysiology Market is expected to register a CAGR of 8.5% during the forecast period.

Dexcom released a hidden camera video showing the shocked reactions of people asked to prick their finger before eating, a task that most people with diabetes do more than eight times per day to check their glucose levels.

The video is part of the company’s national #NoMoreFingerpricks campaign to raise critical awareness about the complexity and seriousness of diabetes and to advocate for innovative technologies like continuous glucose monitoring (CGM) to become the standard in patient care.

“We filmed this video to show the world the unnecessary painfulness of fingerpricks many people with diabetes do every day,” said Kevin Sayer, president and CEO of Dexcom. “With almost 1.5 million people in the United States living with Type 1 diabetes, it is critical that healthcare providers talk to their patients about CGM and other innovative diabetes management technologies that can improve the health and quality of life for people with diabetes.”

Data from a survey released last month shows there is low awareness of CGM among people with Type 1 diabetes, despite the fact CGM eliminates painful fingerpricks, increases time in target glucose range, lowers A1C, decreases hypoglycemia and improves overall quality of life for people with diabetes.1-5

In addition to filming the video, Dexcom launched a social media campaign on November 1 which reached millions of people around the world and raised $25,000 for diabetes advocacy and research. For every photo or video posted to Facebook and Instagram using the hashtag #NoMoreFingerpricks, Dexcom committed to donating $1 to Beyond Type 1, a diabetes nonprofit working to educate, advocate and cure Type 1 diabetes.

“We’re grateful for the revolutionary new technology that is now available to people with Type 1 diabetes,” said Thom Scher, Beyond Type 1 CEO. “It was an inspiring experience to celebrate National Diabetes Awareness Month with Dexcom who is on the forefront of innovation in diabetes technology. This generous donation will help our organization continue to provide critical resources and support to the diabetes community.”


References

  1. Šoupal J, Petruželková L, Fleka M et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technology & Therapeutics. 2016;18(9):532-538.
  2. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomised Clinical Trial. JAMA. 2017;317(4):371-378.
  3. Lind M, Polonsky W, Hirsch IB, et al. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomised Clinical Trial. JAMA. 2017;317(4):379-387.
  4. Reddy M, Jugnee N, El Laboudi A, Spanudakis E, Anantharaja S, Oliver N. A randomised controlled pilot study of continuous glucose monitoring and flash glucose monitoring in people with Type 1 diabetes and impaired awareness of hypoglycaemia. Diabet Med. 2017.
  5. Heinemann L, Freckmann G, Ehrmann D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet. 2018.
spot_img

DON'T MISS

Aethlon Medical Announces Peer-Reviewed Publication of Two Case Studies of Critically Ill COVID-19 Patients Treated with the Hemopurifier®

The publication documents two critically ill COVID-19 patients receiving a combined total of nine, six-hour Hemopurifier® treatment sessions.

Koya Medical Presents Positive Interim Data from Randomized Trial Comparing its Dayspring Lymphedema Treatment to Pneumatic Compression

For people with lymphedema, movement is important from both a clinical perspective and a quality-of-life perspective. These data illustrate the Dayspring treatment’s ability to provide that essential movement while still delivering the clinical outcomes we need from compression therapy.

18-Month Below-the-Knee Data with MedAlliance’s SELUTION SLR™ Presented as Late Breaking Trial at VIVA

“We have observed minimal slow-flow phenomena, seen with other paclitaxel drug-eluting balloons.  We have observed several cases of fast wound healing with SELUTION SLR. It is easy to track and deliver. We are looking forward to gaining further clinical experience with this device,” commented Prof. Chong.

Our Sister Publication: Biotechnology News Magazine

By using this website you agree to accept Medical Device News Magazine Privacy Policy